0
Tobacco Cessation and Prevention |

Results From Male Patients in a Tobacco Cessation Consulting Room in Albacete University Hospital During 2008 and 2009

Francisco Javier Callejas Gonzalez*, MD; Javier Cruz Ruiz, MD; Sergio Garcia Castillo, MD; Mariela Plenc Ziegler, MD; Abel Jesus Martinez Garcia, MD; Juan Pastrana Calderon, MD; Marta Genoves Crespo, MD; Maria Dolores Garcia Jimenez, MD; Ana Isabel Tornero Molina, MD; Manuel Martinez Riaza, MD
Author and Funding Information

Complejo Hospitalario Universitario de Albacete, Albacete, Spain


Chest. 2012;142(4_MeetingAbstracts):1084A. doi:10.1378/chest.1357465
Text Size: A A A
Published online

Abstract

SESSION TYPE: Tobacco Cessation and Prevention Posters

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: Review some of the results analyzed in a Tobacco Cessation Consulting Room during 2008 and 2009.

METHODS: Retrospective descriptive analysis of the results obtained from male patients who were attended in a Tobacco Consulting Room from January 1st in 2008 to December 31 in 2009 and the subsequent follow-up to complete a year.

RESULTS: 300 of 558 patients were males (53.7%), mean age 47.95 years (DE 11.76) and mean cigarettes/day 29.49 (DE 13.31). 77% tried to quit smoking at least once. Moderate-severe nicotine dependence (mean Fagerström 6.08 (DE 2.04)), high motivation (mean Richmond 8.22 (DE 1.35)) and mean initial cooximetry, 17.36 ppm (DE 9.35). Respiratory comorbidity, 30% (18.7% COPD, 6.7% asthma, 15.7% OSAHS and 1% HOT), cardiac comorbidity, 7.83% (IC 9.3% and arrhythmia 2.1%) and psychiatric, 29.7% (23.3% depression and/or anxiety). CVRF: 33% dyslipidemia, 25.3% HT and 12.7% DM. Of 300 male, 146 (48.7%) did not attend the second consultation. 30.5% without treatment, 43.9% NRT or bupropion and 25.6% varenicline. Success among respiratory patients was longer compared with cardiac (25% vs. 4%, non s.s) and among OSAHS males compared no-OSAHS (34.3% vs. 16.13, p<0.044). Those who were treated pharmacologically, greater success statistically significant among who used varenicline compared to NRT or bupropion (36.3% vs. 17.11%, p<0.034. Overall of the 300 males, treatment success in 47 (15.7%); if we do not consider those who did not attend the second consultation, of 154 males who were treated, percentage rises to 30.5%.

CONCLUSIONS: 1. Males showed moderate-severe nicotine dependence and high motivation 2. Severe comorbidity, especially psychiatric, respiratory and CVRF. 3. Greater success among respiratory than cardiac males. 4. Greater success s.s. among OSAHS males compared no-OSAHS. 5. Greater success among varenicline than NRT or bupropion-treated. 6. Overall treatment success 15.7%, amounting to 30.5% excluding those who do not attend the second consultation.

CLINICAL IMPLICATIONS: When patients attend our Tobacco Cessation Consulting Room, they have often severe comorbidity. Smoking cessation treatment is effective but it requires patients commitment. There is an overall use of medication success of 15.7%, rising up to 30.5% if we exclude those who did not attend the second consultation. In our sample, males treated with varenicline showed a success rate higher than the ones treated with bupropion or nicotine replacement therapy.

DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas Gonzalez, Javier Cruz Ruiz, Sergio Garcia Castillo, Mariela Plenc Ziegler, Abel Jesus Martinez Garcia, Juan Pastrana Calderon, Marta Genoves Crespo, Maria Dolores Garcia Jimenez, Ana Isabel Tornero Molina, Manuel Martinez Riaza

No Product/Research Disclosure Information

Complejo Hospitalario Universitario de Albacete, Albacete, Spain

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543